Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.37 |
| ▸ | MPL | P40238 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898443 | 0.86 | ALDH1A1 (0.45) | ALDH1A1ADORA2AADORA1MPL | |
| SCHEMBL20738436 | 0.83 | ALDH1A1 (0.47) | ALDH1A1ADORA2AADORA1KMOHDAC1 | |
| SCHEMBL21811276 | 0.79 | KMO (0.57) | ALDH1A1ADORA2AADORA1KMOHDAC1 | |
| SCHEMBL1582795 | 0.78 | MPL (0.53) | ALDH1A1ADORA2AMPL | |
| SCHEMBL11906681 | 0.78 | KMO (0.56) | ALDH1A1ADORA2AADORA1KMOHDAC1 | |
| SCHEMBL9887058 | 0.77 | TDP1 (0.54) | ALDH1A1ADORA2AADORA1KMOHDAC1 | |
| SCHEMBL23190261 | 0.76 | HDAC1 (0.47) | ALDH1A1ADORA2AADORA1KMOHDAC1 | |
| SCHEMBL3923995 | 0.75 | KMO (0.45) | ALDH1A1ADORA2AADORA1KMOALPL | |
| SCHEMBL13261826 | 0.75 | KMO (0.51) | ADORA2AADORA1KMOALPLF2RL3 | |
| SCHEMBL21811205 | 0.74 | ALPL (0.54) | KMOHDAC1HDAC2ALPLF2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021016413-A1 | SYNTHESIS OF BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | ALKERMES, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | NPY1R, NPY2R, NPY5R | ALDH1A1 1680/4885ADORA2A 1506/4885ADORA1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.